Published • loading... • Updated
Two Child Deaths in China Gene Trials Spur Tighter Rules
The new rules add penalties and tighter hospital oversight after investigators said the trials breached ethics and lacked transparency.
- Two children died in separate investigator-initiated gene-editing trials in China, with both fatalities initially kept quiet before triggering investigations into researchers and institutions.
- In March 2025, a six-year-old girl died after receiving a $1.2 million experimental brain-directed gene therapy at Xinhua Hospital; HuidaGene Therapeutics separately announced a boy's death from its trial in August.
- Investigator-Initiated trials previously allowed rapid testing without national regulatory approval until China enacted Order 818 on May 1, restricting such trials to top-level hospitals and adding new assessment mechanisms.
- Nature is investigating its publication of a Shanghai Jiao Tong University study that failed to disclose the girl's death, while researchers face scrutiny for omitting the fatality from the preclinical manuscript.
- Experts warn these ethical breaches damage the credibility of Chinese institutions, creating urgent pressure to balance biomedical innovation with robust patient safety protections in gene-therapy research.
Insights by Ground AI
11 Articles
11 Articles
MedPage TodayReposted by 
geneticliteracyproject.org
geneticliteracyproject.orgThe Promise and Peril of Gene Editing
Ethical and regulatory guardrails must protect patients amid desperation and scientific optimism
·New York, United States
Read Full Article
Two children died from gene therapies in China: where the field goes next
Nature, Published online: 08 September 2026; doi:10.1038/d41586-026-02497-2Strengthened laws should help to ensure future deaths are quickly disclosed to the public, but China’s reputation for such research is at risk.
·London, United Kingdom
Read Full Article
News: Brain-directed gene editing ends in death
A six-year-old girl died after receiving an experimental CRISPR-Cas base-editing treatment for a nonfatal neurodevelopmental disorder in China. The fatal immune reaction followed preclinical safety findings of liver and kidney damage that experts say should have prompted further investigation.
Coverage Details
Total News Sources11
Leaning Left0Leaning Right1Center5Last UpdatedBias Distribution83% Center
Bias Distribution
- 83% of the sources are Center
83% Center
C 83%
R 17%
Factuality
To view factuality data please Upgrade to Premium
